Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Read more

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Read more

IPO

IPO Calliditas Therapeutics

Read more

Press releases

• Aug 16, 2018Interim Report Q2, 2018
• Aug 13, 2018Calliditas Therapeutics to host conference call to provide Q2 2018 Business Update
• Aug 6, 2018The 15th International Symposium on IgA nephropathy accepts Calliditas Therapeutics abstracts

All press releases

Interim Report Q2 2018

On August 16, 2018, Calliditas Therapeutics published its interim report for the second quarter of 2018.

• Report
• Presentation
• Webcast

Read the report

Calendar

• Nov 1, 2018Interim report for the period January 1 – September 30, 2018
• Feb 7, 2019Year-end report for the period January 1 – December 31, 2018

All events